Blue Trust Inc. Has $73,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Blue Trust Inc. lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 140.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,755 shares of the company’s stock after buying an additional 1,024 shares during the period. Blue Trust Inc.’s holdings in Moderna were worth $73,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB raised its holdings in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares in the last quarter. Larson Financial Group LLC increased its holdings in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares in the last quarter. Rakuten Securities Inc. raised its position in Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after purchasing an additional 778 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the last quarter. Finally, Brooklyn Investment Group bought a new position in Moderna in the third quarter valued at about $80,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

NASDAQ MRNA opened at $35.53 on Monday. The business has a 50 day simple moving average of $38.04 and a 200 day simple moving average of $52.46. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The stock has a market capitalization of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 over the last 90 days. Company insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research report on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a research report on Friday, February 14th. Finally, Berenberg Bank raised their price objective on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.